GlassScriptPhysician profile
Kyle J Osborn
NPI 1538796701
$1,064.63
in general payments reported to CMS, 2019-2025
14 companies · $611 in 2025
The $611 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $69.00 · 2024: $385 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,064.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $202.80 | 2023-2025 | |
| Novo Nordisk INC | $168.52 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $135.41 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $117.52 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $98.69 | 2024-2025 | |
| Lilly USA, LLC | $91.31 | 2024-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $61.43 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.53 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.99 | 2024-2025 | Ofev, Jardiance |
| Madrigal Pharmaceuticals | $28.24 | 2025 | Rezdiffra |
| Philips North America LLC | $22.80 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Ars Pharmaceuticals Operations, INC. | $18.11 | 2025 | Neffy |
| Ibsa Pharma INC. | $17.54 | 2024 | Tirosint, Licart |
| Exact Sciences Corporation | $14.74 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Osborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.